Skip to main content

TDOC STOCK WRITE UP


TDOC (TELADOC, INC)

  • P/E: n/a
  • GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $.1
  • SECTOR: HEALTH SERVICES
  • ASSETS-LIABILITIES: 22
  • DIVIDEND: none

TDOC is the ticker for Teladoc, a telemedicine company specializing in subscription services. The company provides companies access to consult with licensed physicians 24 hours a day with the subscription model. A recent IPO, TDOC is not yet profitable, and has consistent revenue growth.
TDOC increased its revenue 60% on a year-over-year basis when it reported last 5/8/17. They increased advertising budget nearly 50% to support strong revenue growth, while their “legal” budget was diminished significantly. “Technology and development” increased about 25%, and sales costs increased 50%. While overall net loss actually increased on a year-over-year basis, EPS was reported as increased due to an increase in the amount of shares outstanding. The reported EPS beat wall street expectations, and revenue beat expectations by a larger margin. Revenue has increased on a year-over-year basis by 59% or more since Q2 '15, according to TDOC's investor relations website. TDOC reports that it has 22 times as many assets as it does liabilities, and has more than three times as much cash on hand as long-term debt.
Founded in 2002 by George Brooks, Teladoc went public 7/1/15. Jason Gorevic is the CEO. Teladoc has not announced a plan as to when it will become profitable. Teladoc gains some business over competitors by offering a subscription pay rate for employers which its competitors lack, according to seekingalpha. TDOC reports that 80% of its revenue is derived from this subscription service.
It is impossible to determine whether or not Teladoc is overvalued for its specific service as it is the only telemedicine company listed on the NYSE. Revenue has been steadily increasing and the company is not yet profitable as it continues to spend heavily on sales and marketing in order to continue its revenue growth. Teladoc reports 8/16/17, and is expected to declare a loss of $.26 per share, according to CNN money.

SOURCES:







Labels:

Comments

Post a Comment

Popular posts from this blog

ISRG STOCK WRITE UP

ISRG (INTUITIVE SURGICAL INC) P/E: 48 GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $1.13 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 7.05 DIVIDEND: none ISRG is the ticker for Intuitive Surgical Inc, a company endeavoring in the manufacture and distribution of robotic surgical devices. The company recently gained FDA approval for a lower-cost device. They have a clean balance sheet with a history of upside surprises against earnings expectations, and report again 7/20/17. Revenues increased nearly 14%, while EPS increased 32% compared to the Q1 '16 results. While liabilities decreased on a year-over-year basis, assets decreased by a larger margin. R&D spending increased 36%, and administrative costs rose 16%. Taxes were cut in half, although the revenues increased, due to modified accounting principles, and tax benefits for the employee share-based compensation.. The ratio of assets-liabilities decreased from 9.14 to 7.05, which is...
1 comment
Read more

AMGN STOCK WRITE UP

AMGN P/E: 16.1 GAAP EPS Y-O-Y GROWTH LAST QUARTER: $.22 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 1.62 DIVIDEND: 2.54% Amgen is a leading biotech company with a solid financial foundation. It has managed to reduce its spending on research and development while increasing revenue through its sales of established drugs such as Enbrel, and Prolia. The company has several rapidly growing drugs that are newer to the market, with many drugs in the company's pipeline. In its last quarter, Amgen posted 7.7% revenue growth with 7.5% net income growth. The company spent less, however, in the most recent quarter when compared with the comparable quarter from the prior year, on research and development. The reduction in operating margin came from an increased interest expense in the quarter. Although the company spent less on research and development, its revenue did increase. Amgen is continuing to innovate despite reduced research and development b...
Post a Comment
Read more

PXD STOCK WRITE UP

 PXD (PIONEER NATURAL RESOURCES) P/E: N/A GAAP DILUTED Y-O-Y EPS GROWTH LAST QUARTER: $.67 SECTOR: ENERGY MINERALS ASSETS-LIABILITIES: 1.58 DIVIDEND: .04% Pioneer Natural Resources has recently made the jaw-dropping switch from negative EPS to positive with its last quarter. Situated in the largest oil-producing region in the US, the company is utilizing its good fortune to produce profits. The company has a good balance sheet, a wealth of resources, and a business model which has afforded it growth. This last quarter does not mark the first occasion on which Pioneer has posted a profit. In 2014, and 2012, Pioneer posted a positive EPS for the full year. While the 2016 oil and gas revenues have grown from 2015, the 2014 and 2012 levels were higher. The company's revenue from oil and gas is largely based on market prices. In order to mitigate the market volatility, Pioneer has made efforts to reduce their cost of production, according to their earnin...
1 comment
Read more